BRPI0513444A - antagonistas do receptor da histamina 3 - Google Patents

antagonistas do receptor da histamina 3

Info

Publication number
BRPI0513444A
BRPI0513444A BRPI0513444-7A BRPI0513444A BRPI0513444A BR PI0513444 A BRPI0513444 A BR PI0513444A BR PI0513444 A BRPI0513444 A BR PI0513444A BR PI0513444 A BRPI0513444 A BR PI0513444A
Authority
BR
Brazil
Prior art keywords
disorder
compound
formula
disease
histamine
Prior art date
Application number
BRPI0513444-7A
Other languages
English (en)
Inventor
Harry Ralph Howard Jr
Travis T Wager
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0513444A publication Critical patent/BRPI0513444A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ANTAGONISTAS DO RECEPTOR DA HISTAMINA 3 A invenção é direcionada a um composto de fórmula 1 conforme aqui definido, ou a um sal farmaceuticamente aceitável seu, uma composição farmacêutica contendo um composto de fórmula I, um método de tratamento de um distúrbio ou condição que possa ser tratado pelo antagonismo dos receptores de histamina H3, o método compreendendo a administração a um mamífero necessitado de tal tratamento de um composto de fórmula I conforme descrito acima, e um método de tratamento de um distúrbio ou condição selecionado do grupo consistindo de depressão, distúrbios de humor, esquizofrenia, distúrbios de ansiedade, doença de Alzheimer, distúrbio de déficit de atenção (ADD), distúrbio de híperatividade de déficit de atenção (ADHD), distúrbios psicóticos, distúrbios de sono, obesidade, vertigem, epilepsia, doença motora, doenças respiratórias, alergia, respostas das vias aéreas induzidas por alergia, rinite alérgica, congestão nasal, congestão alérgica, congestão, hipotensão, doença cardiovascular, doenças do trato GI, hiper e hipomotilidade e secreção ácida do trato gastrintestinal, o método compreendendo a administração a um mamífero necessitado de tal tratamento de um composto de fórmula I conforme descrito acima.
BRPI0513444-7A 2004-07-21 2005-07-11 antagonistas do receptor da histamina 3 BRPI0513444A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58989304P 2004-07-21 2004-07-21
PCT/IB2005/002186 WO2006011043A1 (en) 2004-07-21 2005-07-11 Histamine-3 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0513444A true BRPI0513444A (pt) 2008-05-06

Family

ID=35124513

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513444-7A BRPI0513444A (pt) 2004-07-21 2005-07-11 antagonistas do receptor da histamina 3

Country Status (7)

Country Link
US (1) US20060019998A1 (pt)
EP (1) EP1771449A1 (pt)
JP (1) JP2008506766A (pt)
BR (1) BRPI0513444A (pt)
CA (1) CA2573920A1 (pt)
MX (1) MX2007000763A (pt)
WO (1) WO2006011043A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
WO2006124897A2 (en) * 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
JP2008540575A (ja) * 2005-05-13 2008-11-20 レキシコン・ファーマシューティカルズ・インコーポレーテッド 多環系化合物とその使用の方法
US8119668B2 (en) * 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US7728031B2 (en) * 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
CN101522614B (zh) 2006-08-09 2014-06-25 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的化合物
TW200827345A (en) * 2006-11-07 2008-07-01 Lexicon Pharmaceuticals Inc (R)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use
US20080139598A1 (en) * 2006-11-07 2008-06-12 Joseph Barbosa Amine-linked Multicyclic Compounds and Methods of Their Use
WO2008067121A2 (en) * 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
TW200823193A (en) * 2006-11-07 2008-06-01 Lexicon Pharmaceuticals Inc (S)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use
RU2486187C2 (ru) * 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
AU2010213794A1 (en) * 2009-02-10 2011-09-01 Abbott Laboratories Agonists and antagonists of the S1P5 receptor, and methods of uses thereof
GB201208775D0 (en) 2012-05-18 2012-07-04 Uni I Oslo Chemical compounds
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
GB201320506D0 (en) 2013-11-26 2014-01-01 Uni I Oslo Cyclic amino compounds for the use in the treatment of cardiac disorders
CA3185336A1 (en) * 2017-11-06 2019-05-09 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
TWI657825B (zh) * 2018-04-04 2019-05-01 美進醫藥公司 治療心血管疾病的組合藥物及其製備和使用方法
US10781172B2 (en) 2018-06-21 2020-09-22 Northwestern University Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
US6316475B1 (en) * 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications

Also Published As

Publication number Publication date
EP1771449A1 (en) 2007-04-11
CA2573920A1 (en) 2006-02-02
US20060019998A1 (en) 2006-01-26
WO2006011043A1 (en) 2006-02-02
JP2008506766A (ja) 2008-03-06
MX2007000763A (es) 2007-03-28

Similar Documents

Publication Publication Date Title
BRPI0507374A (pt) moduladores do receptor de histamina-3
EA200800946A1 (ru) Антагонисты рецептора гистамина-3
BRPI0513486A (pt) derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3
ATE488496T1 (de) Histamin-3-rezeptorantagonisten
WO2007088450A3 (en) Chromane antagonist of the h-3 receptor
WO2007105053A3 (en) Tetralines antagonists of the h-3 receptor
WO2007138431A3 (en) Azabicyclic ether histamine-3 antagonists
WO2007063385A3 (en) Spirocyclic amine histamine-3 receptor antagonists
BRPI0510501A (pt) antagonistas do receptor 3 de histamina
CN106102737B (zh) 色甘酸衍生物以及成像和治疗的相关方法
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
WO2005079802A8 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
MX2009007782A (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma.
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
RU2005135016A (ru) Производные хинолина в качестве ингибиторов фосфодиэстеразы
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
JP2017503765A (ja) ガバペンチノイドおよびシグマ受容体の組み合わせ
EA201170352A1 (ru) Способы лечения расстройств цнс
ATE410163T1 (de) Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens
EP1749532A4 (en) MEDICINAL PRODUCTS FOR HEALING OR TREATING WOUNDS
BRPI0516079A (pt) antagonistas de receptor de histamina-3
BRPI0512567A (pt) compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
BRPI0514820A (pt) antagonistas de receptor de histamina-3 amina azabicìclicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.